Teleflex (TFX)
(Delayed Data from NYSE)
$206.64 USD
+4.13 (2.04%)
Updated May 30, 2024 04:00 PM ET
After-Market: $206.45 -0.19 (-0.09%) 7:30 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$206.64 USD
+4.13 (2.04%)
Updated May 30, 2024 04:00 PM ET
After-Market: $206.45 -0.19 (-0.09%) 7:30 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Teleflex COMFORT FLO System's Voluntary Recall Ranked Class I
by Zacks Equity Research
Teleflex's (TFX) COMFORT FLO Humidification System up for worldwide voluntary recall after the receipt of complaints of device malfunction.
Teleflex's Bipolar Temporary Pacing Guidewire Gets FDA Nod
by Zacks Equity Research
Teleflex (TFX) receives the FDA clearance for its bipolar temporary pacing guidewire, thus paving the way for improvements in TAVR and BAV procedures.
Teleflex (TFX) Receives FDA Nod for Expanded Use of UroLift
by Zacks Equity Research
Teleflex (TFX) receives FDA clearance for expanded indication for the utilization of the UroLift System for treating larger prostrates in men.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international performance in Q3.
Teleflex Hits New 52-Week High: What's Driving the Rally?
by Zacks Equity Research
Teleflex (TFX) is optimistic about maintaining growth momentum on several recent developments.
Teleflex (TFX) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
We are encouraged by Teleflex's (TFX) robust improvement in Q3 revenues on balanced growth across majority of segments and all geographies.
Teleflex (TFX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 8.00% and 0.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More
by Urmimala Biswas
Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.
Teleflex (TFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Teleflex (TFX) Stock Now
by Zacks Equity Research
Investor confidence is still high on Teleflex (TFX), thanks to solid prospects.
Teleflex (TFX) Up 0.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.
Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.
Teleflex (TFX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 2.70% and 2.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.
GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View
by Zacks Equity Research
Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.
Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View
by Zacks Equity Research
Omnicell (OMCL) aims at product innovation through R&D.
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.
Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.
Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand
by Zacks Equity Research
It is encouraging to note that Chemed (CHE) witnessed solid revenue growth across both of its key subsidiaries.
ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.
Teleflex (TFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (ALGN) Beats on Q2 Earnings, Margins Fall
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies.